CN109641858A - 间苯二酚类衍生物的结晶、盐及其制备方法 - Google Patents

间苯二酚类衍生物的结晶、盐及其制备方法 Download PDF

Info

Publication number
CN109641858A
CN109641858A CN201780044038.0A CN201780044038A CN109641858A CN 109641858 A CN109641858 A CN 109641858A CN 201780044038 A CN201780044038 A CN 201780044038A CN 109641858 A CN109641858 A CN 109641858A
Authority
CN
China
Prior art keywords
compound
formula
cancer
acid
crystal form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780044038.0A
Other languages
English (en)
Other versions
CN109641858B (zh
Inventor
颜小兵
黄巍
李丹
丁照中
刘飞
张喜全
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhenjiang Luotai Chemical Technology Co ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN109641858A publication Critical patent/CN109641858A/zh
Application granted granted Critical
Publication of CN109641858B publication Critical patent/CN109641858B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

提供(I)的间苯二酚类衍生物的结晶、盐及其制备方法，以及所述结晶在制备治疗HSP90蛋白介导的疾病药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN201780044038.0A 2016-07-21 2017-07-20 间苯二酚类衍生物的结晶、盐及其制备方法 Active CN109641858B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610581808 2016-07-21
CN2016105818082 2016-07-21
PCT/CN2017/093674 WO2018014858A1 (zh) 2016-07-21 2017-07-20 间苯二酚类衍生物的结晶、盐及其制备方法

Publications (2)

Publication Number Publication Date
CN109641858A true CN109641858A (zh) 2019-04-16
CN109641858B CN109641858B (zh) 2021-06-25

Family

ID=60991957

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780044038.0A Active CN109641858B (zh) 2016-07-21 2017-07-20 间苯二酚类衍生物的结晶、盐及其制备方法

Country Status (3)

Country Link
US (1) US10851071B2 (zh)
CN (1) CN109641858B (zh)
WO (1) WO2018014858A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019262979B2 (en) 2018-05-01 2023-07-06 Revolution Medicines, Inc. C26-linked rapamycin analogs as mTOR inhibitors
WO2022216900A2 (en) * 2021-04-09 2022-10-13 Revolution Medicines, Inc. Synthesis of rapamycin analog compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1771235A (zh) * 2003-02-11 2006-05-10 弗奈利斯(剑桥)有限公司 异噁唑化合物
WO2007021966A1 (en) * 2005-08-12 2007-02-22 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate hsp90 activity
CN103724269A (zh) * 2012-10-11 2014-04-16 中国科学院上海药物研究所 苯基1,2-异噁唑或苯基1,2-吡唑类化合物及其用途
WO2016116061A1 (zh) * 2015-01-22 2016-07-28 南京明德新药研发股份有限公司 作为hsp90抑制剂的间苯二酚类衍生物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1771235A (zh) * 2003-02-11 2006-05-10 弗奈利斯(剑桥)有限公司 异噁唑化合物
WO2007021966A1 (en) * 2005-08-12 2007-02-22 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate hsp90 activity
CN103724269A (zh) * 2012-10-11 2014-04-16 中国科学院上海药物研究所 苯基1,2-异噁唑或苯基1,2-吡唑类化合物及其用途
WO2016116061A1 (zh) * 2015-01-22 2016-07-28 南京明德新药研发股份有限公司 作为hsp90抑制剂的间苯二酚类衍生物
CN107108591A (zh) * 2015-01-22 2017-08-29 正大天晴药业集团股份有限公司 作为hsp90抑制剂的间苯二酚类衍生物

Also Published As

Publication number Publication date
CN109641858B (zh) 2021-06-25
US10851071B2 (en) 2020-12-01
US20190284146A1 (en) 2019-09-19
WO2018014858A1 (zh) 2018-01-25

Similar Documents

Publication Publication Date Title
AU2021204278B2 (en) Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
TW202110836A (zh) 固態形式
CN107548394B (zh) 调节激酶的化合物的固体形式
JP6059723B2 (ja) ４−（８−メトキシ−１−（（１−メトキシプロパン−２−イル）−２−（テトラヒドロ−２Ｈ−ピラン−４−イル）−１Ｈ−イミダゾ［４，５−ｃ］キノリン−７−イル）−３，５−ジメチルイソオキサゾールおよびブロモドメイン阻害剤としてのその使用
CN103842340B (zh) 核转运调节剂及其应用
JP5926793B2 (ja) ブロモドメイン阻害剤としてのテトラヒドロキノリン誘導体
CN105339358B (zh) 核转运调节剂及其用途
RU2602071C2 (ru) Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида
CN105492437B (zh) 取代的苯并呋喃基和苯并噁唑基化合物及其用途
TW202110835A (zh) 固態形式
CN108290887A (zh) 用于治疗睡眠相关的呼吸病症的作为task-1和task-2通道阻断剂的2-苯基-3-(哌嗪子基甲基)咪唑并[1,2-a]吡啶衍生物
CN106573906A (zh) 哌啶‑二酮衍生物
CN107922425A (zh) 制备parp抑制剂、结晶形式的方法及其用途
EP3927696B1 (en) Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
CN107759600A (zh) 作为jak抑制剂的吡咯并嘧啶化合物的结晶
CN109790147A (zh) 咪唑衍生物及其在治疗自身免疫或炎性疾病或癌症中的用途
CN109689641A (zh) 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法
CN106687453A (zh) 作为溴结构域抑制剂的四氢喹啉衍生物
CN109641858A (zh) 间苯二酚类衍生物的结晶、盐及其制备方法
CN110003204B (zh) 一种bet蛋白抑制剂、其制备方法及用途
TW530055B (en) Atropisomers 3-heteroaryl-4(3H)-quinazolinones
TW201920160A (zh) ２－（５－（４－（２－嗎啉乙氧基）苯基）吡啶－２－基）－ｎ－芐乙醯胺之固態形式
CN108727340A (zh) 氟取代的吲唑类化合物及其用途
TW202104216A (zh) Plk4抑制劑之結晶型
RU2684278C1 (ru) Фумарат пиридиламина и его кристаллы

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220408

Address after: Beiwan group, Huqiao village, Danyang Development Zone, Zhenjiang City, Jiangsu Province

Patentee after: Zhenjiang Luotai Chemical Technology Co.,Ltd.

Address before: 222062 Yuzhou South Road, Haizhou District, Lianyungang, Jiangsu 369

Patentee before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.